Plus Price Sales Ratio from 2010 to 2025

PSTV Stock  USD 0.68  0.07  9.33%   
Plus Therapeutics Price Sales Ratio yearly trend continues to be fairly stable with very little volatility. Price Sales Ratio will likely drop to 1.22 in 2025. During the period from 2010 to 2025, Plus Therapeutics Price Sales Ratio regression line of quarterly data had mean square error of  329.85 and geometric mean of  5.18. View All Fundamentals
 
Price Sales Ratio  
First Reported
2010-12-31
Previous Quarter
1.29
Current Value
1.22
Quarterly Volatility
18.12599497
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Plus Therapeutics Correlation against competitors.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Latest Plus Therapeutics' Price Sales Ratio Growth Pattern

Below is the plot of the Price Sales Ratio of Plus Therapeutics over the last few years. It is Plus Therapeutics' Price Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Sales Ratio10 Years Trend
Pretty Stable
   Price Sales Ratio   
       Timeline  

Plus Price Sales Ratio Regression Statistics

Arithmetic Mean14.12
Geometric Mean5.18
Coefficient Of Variation128.37
Mean Deviation13.89
Median6.73
Standard Deviation18.13
Sample Variance328.55
Range60.9431
R-Value(0.25)
Mean Square Error329.85
R-Squared0.06
Significance0.35
Slope(0.96)
Total Sum of Squares4,928

Plus Price Sales Ratio History

2025 1.22
2024 1.29
2023 1.12
2021 37.51
2020 29.52
2019 0.47
2018 0.85

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Price Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Sales Ratio 1.29  1.22 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.